>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
组织中miR-25-3p水平联合能谱CT定量参数预测非小细胞肺癌患者肺叶切除术治疗预后的研究
作者:杜亮  金澄宇 
单位:新疆维吾尔自治区人民医院 胸外科, 新疆 乌鲁木齐 830001
关键词:非小细胞肺癌 肺叶切除术 预后 微小RNA 胸部能谱CT 
分类号:R734.2;R814.42
出版年·卷·期(页码):2022·41·第一期(42-48)
摘要:

目的:观察组织中微小RNA-25-3p (miR-25-3p)水平联合能谱CT定量参数预测非小细胞肺癌(NSCLC)患者肺叶切除术治疗预后的效能。方法:回顾性选取我院2017年1月至2019年1月收治的116例NSCLC患者作为研究对象,记录基线资料,并于治疗前检测组织中miR-25-3p水平,行胸部能谱CT检查。患者均行肺叶切除术治疗,随访19~24个月后评估患者预后,以复发为终点事件。根据复发情况将患者分为预后不良组与预后良好组,比较两组基线资料、组织中miR-25-3p水平及能谱CT定量参数,分析组织中miR-25-3p水平联合能谱CT定量参数对NSCLC患者肺叶切除术治疗预后的预测效能。结果:随访19~24个月,平均随访时间(20.68±3.59)个月,116例NSCLC患者复发率为17.24%;经KM法绘制复发曲线显示,20例复发NSCLC患者中位复发时间为18个月(95%置信区间:15.809~20.191个月);初步比较预后不良组与预后良好组基线资料、miR-25-3p及能谱CT定量参数后,经比例风险回归模型分析结果显示,淋巴结转移、TNM分期、miR-25-3p相对表达量、平扫Eff-Z、静脉期及动脉期NIC是NSCLC患者肺叶切除术治疗预后的影响因素(P<0.05);绘制受试者工作特征曲线,结果显示,组织中miR-25-3p水平联合能谱CT定量参数用于预测患者预后的曲线下面积>0.85,有一定预测价值。结论:组织中miR-25-3p水平联合能谱CT定量参数对NSCLC患者肺叶切除术治疗预后有一定预测效能。

Objective: To observe the efficiency of level of microRNA-25-3p(miR-25-3p) in tissues combined with spectral CT quantitative parameters in predicting the prognosis of patients with non-small cell lung cancer(NSCLC) after pulmonary lobectomy.Methods: 116 patients with NSCLC admitted to our hospital from January 2017 to January 2019 were retrospectively selected as the research subjects, the baseline data were recorded, the level of miR-25-3p in tissues was detected before treatment, chest spectral CT was performed. All patients underwent pulmonary lobectomy, the patients were followed up for 19-24 months to evaluate their prognosis, recurrence was taken as the end point. According to the recurrence, the patients were divided into a poor prognosis group and a good prognosis group, baseline data, level of miR-25-3p in tissues and quantitative parameters of spectral CT were compared between the two groups, the predictive efficiency of level of miR-25-3p in tissues combined with spectral CT quantitative parameters on the prognosis of NSCLC patients after pulmonary lobectomy was analyzed.Results: The patients were followed up for 19-24 months, recurrence was taken as the end point, the average follow-up time was(20.68±3.59) months, the recurrence rate of 116 cases of patients with NSCLC was 17. 24%; the recurrence curve was drawn by KM method, in 20 patients with recurrent NSCLC, the recurrence time was 18 months(95% confidence interval:15.809-20.191 months); the baseline data, miR-25-3p and spectral CT quantitative parameters were preliminarily compared between poor prognosis group and good prognosis group, through proportional hazard regression mode analysis, the results showed that lymph node metastasis, TNM stage, relative expression of miR-25-3p, plain scan Eff-Z, NIC in venous phase and arterial phase were the influencing factors of prognosis in patients with NSCLC after pulmonary lobectomy(P<0.05); the receiver operating characteristics curve was drawn, the results showed that the area under the curve of level of miR-25-3p in tissues combined with spectral CT quantitative parameters in predicting the prognosis of patients was greater than 0.85, which had certain predictive value.Conclusion: Level of miR-25-3p in tissues combined with spectral CT quantitative parameters has certain predictive efficiency in predicting the prognosis of NSCLC patients after pulmonary lobectomy.

参考文献:

[1] JONNA S, SUBRAMANIAM D S.Molecular diagnostics and targeted therapies in non-small cell lung cancer(NSCLC):an update[J].Discov Med, 2019, 27(148):167-170.
[2] RELLI V, TREROTOLA M, GUERRA E, et al.Abandoning the notion of non-small cell lung cancer[J].Trends Mol Med, 2019, 25(7):585-594.
[3] 李法升, 闫瑞柯.能谱CT成像对肺癌与炎性肿块鉴别效能的Meta分析[J].中国医学影像学杂志, 2019, 27(3):230-235.
[4] YING L S, DU L B, ZOU R Y, et al.Development of a serum miRNA panel for detection of early stage non-small cell lung cancer[J].Proc Natl Acad Sci U S A, 2020, 117(40):25036-25042.
[5] CHASSAGNON G, BENNANI S, REVEL M P.New TNM classification of non-small cell lung cancer[J].Rev Pneumol Clin, 2017, 73(1):34-39.
[6] 支修益, 石远凯, 于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(1):67-78.
[7] PRABHASH K.Treatment of advanced nonsmall cell lung cancer:first line, maintenance and second line- Indian consensus statement update[J].South Asian J Cancer, 2019, 8(1):1-17.
[8] 董百强, 王谨, 徐裕金, 等.142例早期非小细胞肺癌SBRT长期预后观察[J].中华放射肿瘤学杂志, 2020, 29(6):416-420.
[9] 李婵, 李涛.老年非小细胞肺癌患者预后影响因素分析[J].中华肿瘤防治杂志, 2020, 27(22):1844-1849.
[10] 赵裕欢, 陈东来, 陈勇兵.非小细胞肺癌淋巴结微转移的研究进展[J].中国肺癌杂志, 2018, 21(7):547-552.
[11] 李少雷, 阎石, 马媛媛, 等.第8版TNM分期模式下1851例非小细胞肺癌淋巴结转移的生存分析:队列研究[J].中国胸心血管外科临床杂志, 2018, 25(5):387-392.
[12] ZHANG X Y, WANG Q, ZHANG S J.MicroRNAs in sputum specimen as noninvasive biomarkers for the diagnosis of nonsmall cell lung cancer:an updated meta-analysis[J].Medicine(Baltimore), 2019, 98(6):e14337.
[13] ZENG Z C, LI Y L, PAN Y J, et al.Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis[J].Nat Commun, 2018, 9(1):5395.
[14] GHARAIBEH L, ELMADANY N, ALWOSAIBAI K, et al.Notch1 in cancer therapy:possible clinical implications and challenges[J].Mol Pharmacol, 2020, 98(5):559-576.
[15] 李世荣, 刘艳, 王振明, 等.血清miR-483-5p、miR-21和miR-25检测在非小细胞肺癌诊断中的价值[J].山东医药, 2019, 59(23):19-22.
[16] 张卫强, 赵京, 刘克强, 等.miR-25-3p和PHLPP2在肺腺癌中的表达及其与预后的相关性分析[J].重庆医学, 2020, 49(23):3936-3940.
[17] SUGAWARA H, TAKAYANAGI T, ISHIKAWA T, et al.New fast kVp switching dual-energy CT:reduced severity of beam hardening artifacts and improved image quality in reduced-iodine virtual monochromatic imaging[J].Acad Radiol, 2020, 27(11):1586-1593.
[18] 侯金鹏, 倪晓琼, 徐耀, 等.能谱CT定量参数在肺腺癌分化程度诊断中的价值[J].实用放射学杂志, 2019, 35(8):1233-1236, 1261.
[19] ZENG D, YAO L S, GE Y S, et al.Full-spectrum-knowledge-aware tensor model for energy-resolved CT iterative reconstruction[J].IEEE Trans Med Imaging, 2020, 39(9):2831-2843.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 343110 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364